When will Liraglutide Injection be back in stock?

The FDA lists an estimated recovery date per manufacturer where known; check the FDA note column below. National FDA records do not reflect your local pharmacy's shelf.

How do I get an alert when Liraglutide Injection changes?

Sign up for a change-only email alert on this page, or subscribe to the RSS or JSON feed. You are notified only when the FDA record changes.

← all medications

Liraglutide Injection

Brand names: Liraglutide, Saxenda, Victoza

Category: Endocrinology/Metabolism

Limited 3Available 6Not specified 1

FDA status: Current, To Be Discontinued · Last FDA update: Sep 22, 2026 · First posted: May 14, 2026 (in shortage 4 months) · 4 manufacturers, 10 listed presentations

As of Sep 22, 2026, the FDA lists Liraglutide Injection as being discontinued. Of 10 manufacturer presentations, 3 Limited, 6 Available, 1 Not specified.

Ask your pharmacist: which of the 4 manufacturers below can they order right now, and whether a different strength or form of Liraglutide Injection is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.

Presentation & package NDC	Manufacturer	Availability	FDA note
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) NDC 0169-2800-15	Novo Nordisk, Inc.	Limited	Product will be available until discontinuation in January 2027
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) NDC 0169-4060-12	Novo Nordisk, Inc.	Limited	Estimated shortage duration: TBD
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) NDC 0169-4060-13	Novo Nordisk, Inc.	Limited	Estimated shortage duration: TBD
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) NDC 0143-9144-02	Hikma Pharmaceuticals USA, Inc.	Available	-
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) NDC 0143-9144-03	Hikma Pharmaceuticals USA, Inc.	Available	-
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) NDC 71288-563-84	Meitheal Pharmaceuticals, Inc.	Available	-
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) NDC 71288-563-85	Meitheal Pharmaceuticals, Inc.	Available	-
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) NDC 0480-3667-20	Novo Nordisk, Inc.	Available	Distributed by Teva
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) NDC 0480-3667-22	Novo Nordisk, Inc.	Available	Distributed by Teva
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) NDC 0480-7250-46	Teva Pharmaceuticals USA, Inc.	Not specified	Discontinuation of the manufacture of the drug

Related medications in shortage

Other Endocrinology/Metabolism medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.

Change log

No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.

Cite this: “FDA drug-shortage status for Liraglutide Injection (FDA data as of Sep 22, 2026). Shortage Watch, openFDA.”

Get an email when this record changes

One email, only when the FDA changes something for Liraglutide Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.

Check your inbox - click the confirmation link to activate alerts for Liraglutide Injection.

Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.

Embed a live status badge: /badge/liraglutide-injection.svg

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).